Skip to main content
TipRanks
Go Ultimate75% OFF

CNS Pharmaceuticals (CNSP) Ratios

1,099 Followers

CNS Pharmaceuticals Ratios

CNSP's free cash flow for Q3 2026 was $-2.77M. For the 2026 fiscal year, CNSP's free cash flow was increased by $0.00 and operating cash flow was $-2.77M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Mar 25Mar 24Dec 22Dec 21
Liquidity Ratios
Current Ratio1.983.430.262.553.50
Quick Ratio1.983.430.262.553.50
Cash Ratio1.762.560.092.042.34
Solvency Ratio-3.86-5.88-3.07-3.10-6.78
Operating Cash Flow Ratio-3.37-6.78-2.31-2.15-6.34
Short-Term Operating Cash Flow Coverage-42.03-52.48-47.01-25.75-34.91
Net Current Asset Value$ 4.00M$ 6.13M$ -4.54M$ 7.64M$ 5.34M
Leverage Ratios
Debt-to-Assets Ratio0.040.040.180.030.04
Debt-to-Equity Ratio0.070.05-0.070.050.06
Debt-to-Capital Ratio0.070.05-0.070.050.06
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.911.41-0.381.601.32
Debt Service Coverage Ratio-46.05-43.36-59.95-36.58-36.45
Interest Coverage Ratio-1049.68-924.50-1366.54-2125.08-1560.14
Debt to Market Cap0.140.140.000.000.00
Interest Debt Per Share0.7810.740.050.180.28
Net Debt to EBITDA0.430.410.010.630.32
Profitability Margins
Gross Profit Margin0.00%0.00%0.00%0.00%0.00%
EBIT Margin0.00%0.00%0.00%0.00%0.00%
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
Operating Profit Margin0.00%0.00%0.00%0.00%0.00%
Pretax Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Profit Margin0.00%0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT99.15%99.70%99.93%102.28%100.06%
Return on Assets (ROA)-183.81%-170.76%-1108.34%-117.02%-165.52%
Return on Equity (ROE)-350.48%-240.55%425.33%-187.81%-218.90%
Return on Capital Employed (ROCE)-353.49%-241.26%425.65%-183.61%-218.76%
Return on Invested Capital (ROIC)-329.54%-229.17%456.64%-174.80%-206.66%
Return on Tangible Assets-183.81%-170.76%-1108.34%-117.02%-165.52%
Earnings Yield-680.96%-645.69%-0.01%-0.01%-0.00%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.000.000.000.000.01
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.00
Asset Turnover0.000.000.000.000.00
Working Capital Turnover Ratio0.000.000.000.000.00
Cash Conversion Cycle0.00-242699.61-514934.48-114315.54-42527.19
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding0.00242699.61514934.48114315.5442527.19
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-31.15-537.26-2.27-4.67-9.59
Free Cash Flow Per Share-31.19-537.39-2.27-4.67-9.60
Dividend Paid and CapEx Coverage Ratio-759.90-4086.27-3624.72-2387.57-2355.31
Capital Expenditure Coverage Ratio-759.90-4086.27-3624.72-2387.57-2355.31
Operating Cash Flow Coverage Ratio-42.03-52.48-47.01-25.75-34.91
Operating Cash Flow to Sales Ratio0.000.000.000.000.00
Free Cash Flow Yield-594.12%-743.90%-0.01%-0.01%-0.00%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.15-0.15-12581.28-10655.68-61536.08
Price-to-Sales (P/S) Ratio0.000.000.000.000.00
Price-to-Book (P/B) Ratio0.510.37-53512.2620012.20134702.83
Price-to-Free Cash Flow (P/FCF) Ratio-0.17-0.13-16768.50-15409.27-65857.50
Price-to-Operating Cash Flow Ratio-0.17-0.13-16773.12-15415.72-65885.46
Price-to-Earnings Growth (PEG) Ratio0.000.00226.95-5.288768.89
Enterprise Value Multiple0.290.26-12574.76-10668.17-61630.81
Enterprise Value-4.54M-3.83M237.17B162.75B891.97B
EV to EBITDA0.290.26-12574.76-10668.17-61630.81
EV to Sales0.000.000.000.000.00
EV to Free Cash Flow0.330.22-16768.48-15408.36-65857.16
EV to Operating Cash Flow0.330.22-16773.11-15414.81-65885.12
Tangible Book Value Per Share10.20193.91-0.713.604.69
Shareholders’ Equity Per Share10.20193.91-0.713.604.69
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share0.000.000.000.000.00
Net Income Per Share-35.75-466.45-3.03-6.76-10.27
Tax Burden1.001.001.001.001.00
Interest Burden1.001.001.001.001.00
Research & Development to Revenue0.000.000.000.000.00
SG&A to Revenue0.000.000.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.000.00
Income Quality0.871.150.750.690.93

Currency in USD